Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Abroad (travel likely)SuspendedPHASE1, PHASE2
Conditions
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Recurrent Acute Myeloid Leukemia · Recurrent Myelodysplastic Syndrome · Refractory Acute Myeloid Leukemia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
M D Anderson Cancer Center, Houston, Texas, United States
Study leads
Musa Yilmaz
Principal Investigator
M.D. Anderson Cancer Center
View source on ClinicalTrials.gov(opens in a new tab)
No study contact email or phone is listed for this trial.